| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TXK |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TXK抗体的3篇代表性文献示例(注：以下内容为模拟生成，部分文献信息可能需要根据实际研究进一步核实)：
---
1. **"Autoantibodies against TXK in systemic lupus erythematosus patients"**
*Kato, H. et al. (2018). Journal of Autoimmunity.*
摘要：研究首次报道了系统性红斑狼疮(SLE)患者血清中存在针对TXK激酶的自身抗体，并发现其与疾病活动性相关。实验表明，TXK抗体可能通过干扰T细胞受体信号通路，加剧自身免疫反应。
2. **"TXK as a therapeutic target in T-cell-mediated autoimmune diseases"**
*Smith, R.J. & Watanabe, T. (2020). Nature Immunology.*
摘要：本文探讨了TXK在Th1和Th17细胞分化中的关键作用，开发了一种靶向TXK的单克隆抗体。动物模型显示，该抗体能显著抑制实验性自身免疫性脑脊髓炎(EAE)的病理进展，提示其治疗潜力。
3. **"Structural basis of TXK kinase inhibition by small molecules"**
*Lee, S. et al. (2022). Cell Chemical Biology.*
摘要：通过晶体学分析揭示了TXK激酶结构域与小分子抑制剂的结合模式，为设计高选择性TXK靶向药物提供了依据。实验证明，抑制剂可阻断T细胞活化，降低炎症因子释放。
---
**备注**：以上文献为示例性质，实际研究中请通过PubMed或Web of Science等平台检索最新论文。建议结合关键词“TXK antibody”“ITK family kinase”“autoimmunity”等进一步筛选。
The TXK antibody targets the TXK protein (also known as RLK), a non-receptor tyrosine kinase belonging to the Tec family. Primarily expressed in T lymphocytes and natural killer (NK) cells, TXK plays a critical role in T-cell receptor (TCR) signaling and immune regulation. Structurally, it contains a pleckstrin homology (PH) domain, SH3 and SH2 domains, and a catalytic kinase domain, enabling interactions with signaling molecules like PLCγ1 and Vav1. TXK activation contributes to cytokine production, cell proliferation, and differentiation, influencing both adaptive and innate immune responses.
Research links TXK dysfunction to autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Overactive TXK signaling may drive pathogenic T-cell hyperactivity and inflammatory cytokine release. Consequently, TXK antibodies have emerged as investigative tools and potential therapeutic agents. In preclinical studies, anti-TXK antibodies inhibit kinase activity, suppress T-cell activation, and ameliorate autoimmune symptoms in animal models. Their clinical relevance is under exploration, particularly for targeted immunotherapy in autoimmune conditions. However, challenges remain in optimizing specificity and minimizing off-target effects. Current studies focus on elucidating TXK's role in disease mechanisms and validating its therapeutic potential through antibody-mediated modulation.
×
